Inotuzumab Ozogamicin
Overview
Inotuzumab ozogamicin is a targeted antibody-drug conjugate used in the treatment of B-cell precursor acute lymphoblastic leukemia. The therapy combines a monoclonal antibody directed against CD22, a surface antigen expressed on malignant B cells, with calicheamicin, a potent cytotoxic antibiotic that causes DNA strand breaks leading to cancer cell death. After binding to CD22-positive leukemia cells, the drug is internalized and releases the cytotoxic payload intracellularly, resulting in apoptosis and inhibition of leukemic cell proliferation. Inotuzumab ozogamicin is administered intravenously and is primarily used in relapsed or refractory disease settings where standard therapies have failed. Its targeted mechanism allows selective delivery of chemotherapy to malignant cells while reducing exposure to normal tissues. The drug has become an important therapeutic option in advanced acute lymphoblastic leukemia, particularly as bridge therapy prior to hematopoietic stem cell transplantation.
Background and Date of Approval
Inotuzumab ozogamicin was developed as a CD22-directed antibody-drug conjugate for treatment-resistant B-cell malignancies. The United States Food and Drug Administration approved inotuzumab ozogamicin on August 17, 2017 for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The approval was based on findings from the Phase III INO-VATE ALL clinical trial, which demonstrated higher remission rates and improved outcomes compared with standard chemotherapy. On March 6, 2024, the United States Food and Drug Administration expanded approval to include pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. Regulatory approvals have also been granted in multiple international regions including the European Union and Japan.
Uses
Inotuzumab ozogamicin is indicated for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia in adults and pediatric patients. It is commonly used in patients who have failed prior chemotherapy or targeted therapy regimens. The drug may also be used as a bridge to stem cell transplantation in eligible patients with responsive disease.
Administration
Inotuzumab ozogamicin is administered as an intravenous infusion in treatment cycles with dosing based on body surface area. The therapy is typically given weekly within each cycle. Premedication with corticosteroids, antipyretics, and antihistamines may be required to reduce infusion-related reactions. Dose adjustments or treatment interruptions may be necessary depending on hematologic toxicity, liver function abnormalities, or other adverse effects. Regular monitoring is required throughout therapy.
Side Effects
Common side effects include thrombocytopenia, neutropenia, anemia, fatigue, nausea, fever, infections, headache, abdominal pain, and elevated liver enzymes. Infusion-related reactions and gastrointestinal symptoms may also occur. These effects are generally manageable with supportive care and close monitoring.
Warnings
Serious adverse reactions include hepatotoxicity, particularly hepatic veno-occlusive disease or sinusoidal obstruction syndrome, which may be severe or fatal. Myelosuppression with severe infections and bleeding complications can occur. Prolonged QT interval, severe infusion reactions, and tumor lysis syndrome have also been reported. Patients proceeding to stem cell transplantation require especially careful liver monitoring due to increased hepatic risk. Embryo-fetal toxicity is also a concern during pregnancy.
Precautions
Patients should undergo baseline liver function testing, complete blood count evaluation, and cardiac assessment before treatment initiation. Caution is required in patients with prior liver disease, previous stem cell transplantation, or pre-existing cardiac abnormalities. Concomitant use with hepatotoxic medications or QT-prolonging agents may increase complication risk. Regular monitoring of liver enzymes, blood counts, electrolytes, and electrocardiograms is recommended during therapy.
Expert Tips
Inotuzumab ozogamicin is particularly valuable in relapsed or refractory acute lymphoblastic leukemia where achieving remission before stem cell transplantation is important. Clinicians should carefully evaluate hepatic risk factors before treatment initiation and transplantation planning. Frequent monitoring of blood counts and liver function is essential throughout therapy. Patient counselling should emphasize early reporting of jaundice, abdominal swelling, fever, or bleeding symptoms. Coordination between hematology, transplant, and supportive care teams is critical for optimizing treatment safety and long-term outcomes.